Recent studies also demonstrate the efficacy of combining CDK4/6 with HSP-90 inhibitors, further inhibiting HIF1 activity and offering potential treatment enhancements for renal and colon cancers (26). This evidence concerns the gene HIF1A and colonic neoplasm.